(Q37579225)

21 August 2017

1 reference

title

Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology (English)

1 reference

21 August 2017

2

Evanthia Galanis

1 reference

21 August 2017

Pavlos Msaouel

1

1 reference

PubMed ID

19678799

21 August 2017

Michael Koutsilieris

series ordinal

3

1 reference

PubMed ID

19678799

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

18

1 reference

21 August 2017

9

1 reference

21 August 2017

1297-1316

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin: electron microscope immunohistochemical localization in secretory neurons of rat hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin and its receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Human somatostatin I: sequence of the cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Molecular cloning and functional expression of a brain-specific somatostatin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Cloning and characterization of a fourth human somatostatin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Classification and nomenclature of somatostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Peptides in the Brain: The New Endocrinology of the Neuron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin and cancer: applying endocrinology to oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin analogs in oncology: a look to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Detection of somatostatin receptors in human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Immunohistochemical localization of somatostatin receptors sst2A in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

21 January 2018

Neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Peptide receptors as molecular targets for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Current status of gastrointestinal carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Management of breast cancer: is there a role for somatostatin and its analogs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin, its receptors and analogs, in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide in the management of hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide for cancer of the liver and biliary tree

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Pancreatic cancer: does octreotide offer any promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptors in non-endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Gastrointestinal cancer refractory to chemotherapy: a role for octreotide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Binding properties of somatostatin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Drug design at peptide receptors: somatostatin receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Vapreotide acetate for the treatment of esophageal variceal bleeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Pasireotide (SOM230): development, mechanism of action and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Luteinising hormone-releasing hormone antagonists in prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Clinical endocrinology and metabolism. Gut endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Established clinical use of octreotide and lanreotide in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Molecular pharmacology of somatostatin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Intracellular trafficking of somatostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Endothelin-converting enzyme-1 degrades internalized somatostatin-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Regulation and function of somatostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Signal transduction of somatostatin receptors negatively controlling cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Receptor isoforms mediate opposing proliferative effects through gbetagamma-activated p38 or Akt pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Mechanisms of bone metastasis in prostate cancer: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Rationale for the use of somatostatin analogs as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Pituitary-independent effect of octreotide on IGF1 generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Skeletal metastases in advanced prostate cancer: cell biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Targeting the growth hormone axis as a therapeutic strategy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The GH-IGF-I axis and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Mechanisms of antineoplastic action of somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Mechanisms of disease: angiogenesis in urologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Molecular basis of metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Clinical approaches toward tumor angiogenesis: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide, the reticuloendothelial system, and experimental liver tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Inhibition of endothelial proliferation by the somatostatin analogue SOM230.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor distribution and function in immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Inhibitory effect of somatostatin on inflammation and nociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Myeloid cells functioning in tumor vascularization as a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The palliative effects of octreotide in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Octreotide: a potent new non-opiate analgesic for intrathecal infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin receptor imaging for neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin analogue phase I trials in neuroendocrine neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

21 January 2018

Somatostatin receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176399

10.1517/13543780903176399

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19678799